Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Mivebresib |
| Trade Name | |
| Synonyms | ABBV-075 |
| Drug Descriptions |
Mivebresib (ABBV-075) is a bromodomain (BET) inhibitor, which may disrupt transcriptional regulation and lead to apaotosis of tumor cells (PMID: 28416490, PMID: 31420359). |
| DrugClasses | BET Inhibitor (Pan) 33 |
| CAS Registry Number | 1445993-26-9 |
| NCIT ID | C121829 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Azacitidine + Mivebresib | Azacitidine Mivebresib | 0 | 0 |
| Bortezomib + Mivebresib | Bortezomib Mivebresib | 0 | 0 |
| Mivebresib | Mivebresib | 0 | 2 |
| Mivebresib + Navitoclax | Mivebresib Navitoclax | 0 | 1 |
| Mivebresib + Obatoclax | Mivebresib Obatoclax | 0 | 0 |
| Mivebresib + Ruxolitinib | Mivebresib Ruxolitinib | 0 | 1 |
| Mivebresib + Venetoclax | Mivebresib Venetoclax | 0 | 0 |